5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts

02. Natera, Inc. (NASDAQ:NTRA)

Price Reaction after the Upgrade: +4.39 (+4.75%)

On April 5, Sanford C. Bernstein made a significant move by upgrading Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, from a “market perform” to an “outperform” rating, while setting a target price of $120.00 for the company. This upgrade triggered a substantial surge in market activity on April 5, with Natera, Inc. (NASDAQ:NTRA)stock witnessing a robust price reaction, climbing by 4.75%. On April 5, Natera, Inc. (NASDAQ:NTRA) revealed findings from the IMvigor011 study at the EAU Congress 2024. The study focused on muscle-invasive bladder cancer (MIBC) patients testing negative with Signatera™, Natera’s MRD test. Sponsored by Genentech, IMvigor011 involved high-risk MIBC patients undergoing serial Signatera testing post cystectomy. MRD-negative patients showed impressive overall survival (OS) rates of 100% at 12 months and 98% at 18 months, with disease-free survival (DFS) rates of 92% at 12 months and 88% at 18 months. John Simmons, Natera, Inc. (NASDAQ:NTRA) Vice President of BioPharma, highlighted the trial’s importance in personalizing MIBC treatment decisions with Signatera. The findings may support Natera, Inc. (NASDAQ:NTRA) FDA submission for Signatera as a companion diagnostic, advancing personalized medicine in MIBC care.